Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA, PD-1 Inhibitor Sponsors Discussing Real-World Study

Executive Summary

Agency would consider a site-agnostic indication for tumors with high mutation burden if results from the proposed pragmatic clinical practice study were positive.

Advertisement

Related Content

FDA Oncology Office Looks To Get Better INFORMED Through Big Data
FDA Oncology Office Looks To Get Better INFORMED Through Big Data
Clinical Trial Endpoints May Not Fit Real-World Studies
Real-World Evidence May Find A Home On Breakthrough Pathway

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS057738

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel